These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 31747237)

  • 1. CKD quality improvement intervention with PCMH integration: health plan results.
    Vassalotti JA; DeVinney R; Lukasik S; McNaney S; Montgomery E; Voss C; Winn D
    Am J Manag Care; 2019 Nov; 25(11):e326-e333. PubMed ID: 31747237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. All-cause costs increase exponentially with increased chronic kidney disease stage.
    Golestaneh L; Alvarez PJ; Reaven NL; Funk SE; McGaughey KJ; Romero A; Brenner MS; Onuigbo M
    Am J Manag Care; 2017 Jun; 23(10 Suppl):S163-S172. PubMed ID: 28978205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Cardiovascular Disease and Chronic Kidney Disease on Life Expectancy and Direct Medical Cost in a 10-Year Diabetes Cohort Study.
    Wan EYF; Chin WY; Yu EYT; Wong ICK; Chan EWY; Li SX; Cheung NKL; Wang Y; Lam CLK
    Diabetes Care; 2020 Aug; 43(8):1750-1758. PubMed ID: 32457057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison between urine albumin-to-creatinine ratio and urine protein dipstick testing for prevalence and ability to predict the risk for chronic kidney disease in the general population (Iwate-KENCO study): a prospective community-based cohort study.
    Koeda Y; Tanaka F; Segawa T; Ohta M; Ohsawa M; Tanno K; Makita S; Ishibashi Y; Itai K; Omama SI; Onoda T; Sakata K; Ogasawara K; Okayama A; Nakamura M
    BMC Nephrol; 2016 May; 17(1):46. PubMed ID: 27169575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timeliness in chronic kidney disease and albuminuria identification: a retrospective cohort study.
    Fraser SD; Parkes J; Culliford D; Santer M; Roderick PJ
    BMC Fam Pract; 2015 Feb; 16():18. PubMed ID: 25879207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of Chronic Kidney Disease Management in Canadian Primary Care.
    Bello AK; Ronksley PE; Tangri N; Kurzawa J; Osman MA; Singer A; Grill AK; Nitsch D; Queenan JA; Wick J; Lindeman C; Soos B; Tuot DS; Shojai S; Brimble KS; Mangin D; Drummond N
    JAMA Netw Open; 2019 Sep; 2(9):e1910704. PubMed ID: 31483474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving care coordination between nephrology and primary care: a quality improvement initiative using the renal physicians association toolkit.
    Haley WE; Beckrich AL; Sayre J; McNeil R; Fumo P; Rao VM; Lerma EV
    Am J Kidney Dis; 2015 Jan; 65(1):67-79. PubMed ID: 25183380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association between the severity of chronic kidney disease and medical costs among patients with type 2 diabetes.
    Lage MJ; Boye KS; Bae JP; Wu J; Mody R; Botros FT
    J Med Econ; 2019 May; 22(5):447-454. PubMed ID: 30736708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reclassification of Chronic Kidney Disease Stage, Eligibility for Cystatin-C and Its Associated Costs in a UK Primary Care Cohort.
    Major RW; Shepherd D; Brunskill NJ
    Nephron; 2018; 139(1):39-46. PubMed ID: 29566373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using pharmacists to improve risk stratification and management of stage 3A chronic kidney disease: a feasibility study.
    Chang AR; Evans M; Yule C; Bohn L; Young A; Lewis M; Graboski E; Gerdy B; Ehmann W; Brady J; Lawrence L; Antunes N; Green J; Snyder S; Kirchner HL; Grams M; Perkins R
    BMC Nephrol; 2016 Nov; 17(1):168. PubMed ID: 27825313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost to government and society of chronic kidney disease stage 1-5: a national cohort study.
    Wyld ML; Lee CM; Zhuo X; White S; Shaw JE; Morton RL; Colagiuri S; Chadban SJ
    Intern Med J; 2015 Jul; 45(7):741-7. PubMed ID: 25944415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical Neighborhood Model for the Care of Chronic Kidney Disease Patients.
    Smith ZG; McNicoll L; Clark TL; Cohen AJ; Ross AL; Monteiro JF; Dworkin LD
    Am J Nephrol; 2016; 44(4):308-315. PubMed ID: 27657555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costs and healthcare use of patients with chronic kidney disease in the Northern Territory, Australia.
    Chen W; Howard K; Gorham G; Abeyaratne A; Zhao Y; Adegboye O; Kangaharan N; Talukder MRR; Taylor S; Cass A;
    BMC Health Serv Res; 2024 Jul; 24(1):791. PubMed ID: 38982437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular readmissions and excess costs following percutaneous coronary intervention in patients with chronic kidney disease: data from a large multi-centre Australian registry.
    Ariyaratne TV; Ademi Z; Duffy SJ; Andrianopoulos N; Billah B; Brennan AL; New G; Black A; Ajani AE; Clark DJ; Yan BP; Yap CH; Reid CM
    Int J Cardiol; 2013 Oct; 168(3):2783-90. PubMed ID: 23643437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healthcare costs in chronic kidney disease and renal replacement therapy: a population-based cohort study in Sweden.
    Eriksson JK; Neovius M; Jacobson SH; Elinder CG; Hylander B
    BMJ Open; 2016 Oct; 6(10):e012062. PubMed ID: 27855091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility analysis of the National Health Screening Program for chronic kidney disease in Korea.
    Go DS; Kim SH; Park J; Ryu DR; Lee HJ; Jo MW
    Nephrology (Carlton); 2019 Jan; 24(1):56-64. PubMed ID: 29206319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of Pneumococcal Vaccination Among Patients With CKD in the United States.
    Ishigami J; Padula WV; Grams ME; Chang AR; Jaar B; Gansevoort RT; Bridges JFP; Kovesdy CP; Uchida S; Coresh J; Matsushita K
    Am J Kidney Dis; 2019 Jul; 74(1):23-35. PubMed ID: 30898360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for chronic kidney disease in Canadian indigenous peoples is cost-effective.
    Ferguson TW; Tangri N; Tan Z; James MT; Lavallee BDA; Chartrand CD; McLeod LL; Dart AB; Rigatto C; Komenda PVJ
    Kidney Int; 2017 Jul; 92(1):192-200. PubMed ID: 28433383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Intensive Blood Pressure Lowering on Kidney Tubule Injury in CKD: A Longitudinal Subgroup Analysis in SPRINT.
    Malhotra R; Craven T; Ambrosius WT; Killeen AA; Haley WE; Cheung AK; Chonchol M; Sarnak M; Parikh CR; Shlipak MG; Ix JH;
    Am J Kidney Dis; 2019 Jan; 73(1):21-30. PubMed ID: 30291012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.